ME02755B - Monociklički derivat piridina - Google Patents
Monociklički derivat piridinaInfo
- Publication number
- ME02755B ME02755B MEP-2017-130A MEP2017130A ME02755B ME 02755 B ME02755 B ME 02755B ME P2017130 A MEP2017130 A ME P2017130A ME 02755 B ME02755 B ME 02755B
- Authority
- ME
- Montenegro
- Prior art keywords
- pyridine derivative
- monocyclic pyridine
- monocyclic
- derivative
- pyridine
- Prior art date
Links
- -1 Monocyclic pyridine derivative Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361766922P | 2013-02-20 | 2013-02-20 | |
EP14754294.8A EP2960238B1 (en) | 2013-02-20 | 2014-02-18 | Monocyclic pyridine derivative |
PCT/JP2014/053819 WO2014129477A1 (ja) | 2013-02-20 | 2014-02-18 | 単環ピリジン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
ME02755B true ME02755B (me) | 2018-01-20 |
Family
ID=51351646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MEP-2017-130A ME02755B (me) | 2013-02-20 | 2014-02-18 | Monociklički derivat piridina |
Country Status (35)
Country | Link |
---|---|
US (1) | US8933099B2 (me) |
EP (1) | EP2960238B1 (me) |
JP (2) | JP5600229B1 (me) |
KR (1) | KR102050128B1 (me) |
CN (1) | CN105073730B (me) |
AR (1) | AR094812A1 (me) |
AU (1) | AU2014219811B2 (me) |
BR (1) | BR112015019790B1 (me) |
CA (1) | CA2901585C (me) |
CL (1) | CL2015002311A1 (me) |
CY (1) | CY1119220T1 (me) |
DK (1) | DK2960238T3 (me) |
ES (1) | ES2628495T3 (me) |
HK (1) | HK1215949A1 (me) |
HR (1) | HRP20170873T1 (me) |
HU (1) | HUE032931T2 (me) |
IL (1) | IL240623B (me) |
JO (1) | JO3261B1 (me) |
LT (1) | LT2960238T (me) |
ME (1) | ME02755B (me) |
MX (1) | MX361870B (me) |
MY (1) | MY178760A (me) |
NZ (1) | NZ711101A (me) |
PE (1) | PE20151509A1 (me) |
PH (1) | PH12015501813A1 (me) |
PL (1) | PL2960238T3 (me) |
PT (1) | PT2960238T (me) |
RS (1) | RS56064B1 (me) |
RU (1) | RU2645352C2 (me) |
SG (1) | SG11201506488WA (me) |
SI (1) | SI2960238T1 (me) |
TW (4) | TWI672140B (me) |
UA (1) | UA116794C2 (me) |
WO (1) | WO2014129477A1 (me) |
ZA (1) | ZA201505941B (me) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015304465B2 (en) | 2014-08-18 | 2019-05-09 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
KR102537152B1 (ko) * | 2015-03-25 | 2023-05-26 | 국립연구개발법인 고쿠리츠간켄큐센터 | 담관암에 대한 치료제 |
EP3391885B1 (en) * | 2015-12-17 | 2021-03-17 | Eisai R&D Management Co., Ltd. | Therapeutic agent for breast cancer |
CN107098884A (zh) * | 2016-02-19 | 2017-08-29 | 中国科学院上海药物研究所 | 一类取代的氨基吡啶类化合物及其制备和用途 |
RU2020108284A (ru) * | 2017-10-12 | 2021-11-12 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Фармацевтическая композиция, содержащая селективный ингибитор тирозинкиназы fgfr |
US11219619B2 (en) | 2018-03-28 | 2022-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic agent for hepatocellular carcinoma |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
MX2022012934A (es) * | 2020-04-17 | 2022-11-08 | Eisai R&D Man Co Ltd | Agente terapeutico para cancer de mama. |
CN115996722A (zh) | 2020-07-31 | 2023-04-21 | 卫材R&D管理有限公司 | 乳腺癌治疗剂 |
TW202233185A (zh) | 2020-10-28 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | 腫瘤治療用醫藥組合物 |
CA3227445A1 (en) * | 2021-08-31 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Production method for synthetic intermediate of monocyclic pyridine derivative |
TW202328099A (zh) | 2021-08-31 | 2023-07-16 | 日商衛材R&D企管股份有限公司 | 單環吡啶衍生物之製造方法 |
AU2023236231A1 (en) * | 2022-03-18 | 2024-09-05 | Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences | Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10006139A1 (de) * | 2000-02-11 | 2001-08-16 | Merck Patent Gmbh | Indol-3-yl-Derivate |
RU2264389C3 (ru) | 2000-10-20 | 2018-06-01 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения |
WO2002081420A1 (fr) | 2001-04-03 | 2002-10-17 | Eisai Co., Ltd. | Derive de cyclooctanone et derive de cyclodecanone et utilisation de ces derives |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2003261807B9 (en) | 2002-08-30 | 2007-02-15 | Eisai R & D Management Co., Ltd. | Azaarene derivatives |
US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
RU2350617C2 (ru) | 2003-04-10 | 2009-03-27 | Ф.Хоффманн-Ля Рош Аг | Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр |
US20050256154A1 (en) | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
FR2883286B1 (fr) | 2005-03-16 | 2008-10-03 | Sanofi Aventis Sa | NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT |
WO2006127926A2 (en) * | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
MEP3808A (xx) | 2005-12-21 | 2010-02-10 | Novartis Ag | Derivati pirimidinil aril uree kao fgf inhibitori |
JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
TW200811134A (en) | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
EP1891955A1 (en) | 2006-07-24 | 2008-02-27 | Sanofi-Aventis | Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases |
US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
US8131527B1 (en) | 2006-12-22 | 2012-03-06 | Astex Therapeutics Ltd. | FGFR pharmacophore compounds |
JP5442449B2 (ja) | 2006-12-22 | 2014-03-12 | アステックス、セラピューティックス、リミテッド | 新規化合物 |
CA2672172C (en) | 2006-12-22 | 2016-05-03 | Astex Therapeutics Limited | Bicyclic heterocyclic compounds as fgfr inhibitors |
CA2690355A1 (en) | 2007-06-25 | 2008-12-31 | Qinetiq Limited | Preconcentrator device incorporating a polymer of intrinsic microporosity |
WO2009019518A1 (en) | 2007-08-09 | 2009-02-12 | Astrazeneca Ab | Pyrimidine compounds having a fgfr inhibitory effect |
GB0720041D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New Compounds |
GB0720038D0 (en) | 2007-10-12 | 2007-11-21 | Astex Therapeutics Ltd | New compounds |
WO2009056886A1 (en) | 2007-11-01 | 2009-05-07 | Astrazeneca Ab | Pyrimidine derivatives and their use as modulators of fgfr activity |
WO2009076660A2 (en) * | 2007-12-13 | 2009-06-18 | Tyratech, Inc. | Organic absorbent material and uses thereof |
CL2008003675A1 (es) * | 2007-12-13 | 2009-03-20 | Wyeth Corp | Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide. |
CN102036963B (zh) | 2008-05-23 | 2013-08-21 | 诺瓦提斯公司 | 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物 |
GB0810902D0 (en) | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
WO2009153592A1 (en) | 2008-06-19 | 2009-12-23 | Astrazeneca Ab | Pyrazole compounds 436 |
WO2010078430A1 (en) | 2008-12-30 | 2010-07-08 | Arqule, Inc. | Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds |
US8263610B2 (en) | 2008-12-30 | 2012-09-11 | Arqule, Inc. | Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds |
DK2379506T3 (en) | 2008-12-30 | 2015-12-14 | Arqule Inc | Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds |
US9002427B2 (en) | 2009-03-30 | 2015-04-07 | Lifewave Biomedical, Inc. | Apparatus and method for continuous noninvasive measurement of respiratory function and events |
GB0906472D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
GB0906470D0 (en) | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
FR2947546B1 (fr) | 2009-07-03 | 2011-07-01 | Sanofi Aventis | Derives de pyrazoles, leur preparation et leur application en therapeutique |
CN102574836B (zh) | 2009-08-07 | 2014-04-16 | 中外制药株式会社 | 氨基吡唑衍生物 |
ES2524548T3 (es) | 2009-10-30 | 2014-12-10 | Novartis Ag | N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea |
AR079257A1 (es) | 2009-12-07 | 2012-01-04 | Novartis Ag | Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
BR112014017749B1 (pt) | 2012-01-19 | 2021-08-03 | Taiho Pharmaceutical Co., Ltd. | Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo |
AR090161A1 (es) | 2012-02-28 | 2014-10-22 | Astellas Pharma Inc | Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
LT3495367T (lt) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai |
BR112015000653A2 (pt) | 2012-07-11 | 2019-11-05 | Blueprint Medicines Corp | compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
WO2014044846A1 (en) | 2012-09-24 | 2014-03-27 | Evotec (Uk) Ltd. | 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia |
WO2014048878A1 (en) | 2012-09-26 | 2014-04-03 | Evotec (Uk) Ltd. | Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia |
RU2673943C2 (ru) | 2012-09-27 | 2018-12-03 | Чугаи Сейяку Кабусики Кайся | Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него |
TWI628176B (zh) | 2013-04-04 | 2018-07-01 | 奧利安公司 | 蛋白質激酶抑制劑 |
-
2014
- 2014-02-17 AR ARP140100495A patent/AR094812A1/es active IP Right Grant
- 2014-02-18 PL PL14754294T patent/PL2960238T3/pl unknown
- 2014-02-18 LT LTEP14754294.8T patent/LT2960238T/lt unknown
- 2014-02-18 CN CN201480009370.XA patent/CN105073730B/zh active Active
- 2014-02-18 HU HUE14754294A patent/HUE032931T2/en unknown
- 2014-02-18 PE PE2015001748A patent/PE20151509A1/es active IP Right Grant
- 2014-02-18 KR KR1020157022252A patent/KR102050128B1/ko active IP Right Grant
- 2014-02-18 EP EP14754294.8A patent/EP2960238B1/en active Active
- 2014-02-18 ES ES14754294.8T patent/ES2628495T3/es active Active
- 2014-02-18 BR BR112015019790-6A patent/BR112015019790B1/pt active IP Right Grant
- 2014-02-18 ME MEP-2017-130A patent/ME02755B/me unknown
- 2014-02-18 SG SG11201506488WA patent/SG11201506488WA/en unknown
- 2014-02-18 PT PT147542948T patent/PT2960238T/pt unknown
- 2014-02-18 TW TW107134529A patent/TWI672140B/zh active
- 2014-02-18 CA CA2901585A patent/CA2901585C/en active Active
- 2014-02-18 DK DK14754294.8T patent/DK2960238T3/en active
- 2014-02-18 WO PCT/JP2014/053819 patent/WO2014129477A1/ja active Application Filing
- 2014-02-18 UA UAA201508149A patent/UA116794C2/uk unknown
- 2014-02-18 SI SI201430247A patent/SI2960238T1/sl unknown
- 2014-02-18 NZ NZ711101A patent/NZ711101A/en unknown
- 2014-02-18 RS RS20170596A patent/RS56064B1/sr unknown
- 2014-02-18 TW TW103105419A patent/TWI641602B/zh active
- 2014-02-18 MX MX2015010698A patent/MX361870B/es active IP Right Grant
- 2014-02-18 TW TW107134526A patent/TWI672139B/zh active
- 2014-02-18 AU AU2014219811A patent/AU2014219811B2/en active Active
- 2014-02-18 MY MYPI2015702696A patent/MY178760A/en unknown
- 2014-02-18 RU RU2015134558A patent/RU2645352C2/ru active
- 2014-02-18 JP JP2014526292A patent/JP5600229B1/ja active Active
- 2014-02-18 JO JOP/2014/0039A patent/JO3261B1/ar active
- 2014-02-18 TW TW107134522A patent/TWI672296B/zh active
- 2014-02-19 US US14/183,864 patent/US8933099B2/en active Active
- 2014-08-14 JP JP2014165311A patent/JP2014237707A/ja active Pending
-
2015
- 2015-08-17 IL IL240623A patent/IL240623B/en active IP Right Grant
- 2015-08-18 PH PH12015501813A patent/PH12015501813A1/en unknown
- 2015-08-18 CL CL2015002311A patent/CL2015002311A1/es unknown
- 2015-08-18 ZA ZA2015/05941A patent/ZA201505941B/en unknown
-
2016
- 2016-04-06 HK HK16103911.2A patent/HK1215949A1/zh unknown
-
2017
- 2017-06-07 HR HRP20170873TT patent/HRP20170873T1/hr unknown
- 2017-06-15 CY CY20171100631T patent/CY1119220T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1215949A1 (zh) | 單環吡啶衍生物 | |
HK1215795A1 (zh) | 鵝膏毒素衍生物 | |
LT2953944T (lt) | Piridazinono amidų dariniai | |
HK1211938A1 (en) | Novel pyridine derivatives | |
HK1220454A1 (zh) | 吡啶- -基衍生物 | |
PL3027598T3 (pl) | Pochodne oksochinazolinylo-butanoamidowe | |
HK1220200A1 (zh) | 乙炔基衍生物 | |
HUE037606T2 (hu) | Imidazopirazinon-származékok | |
EP2966074A4 (en) | morphinan | |
EP3009444A4 (en) | ALPHA-oxoacyl-Amino-caprolactam derivative |